Katerina Chatzidionysiou (K Chatzidionysiou)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 21

Top Topics

Rheumatoid Arthritis

Idiopathic Pulmonary Fibrosis

Disease Activity

Placebo Controlled

Top Venues

Annals of the rheumatic diseases

Arthritis & rheumatology (Hoboken, N.J.)

Scandinavian journal of rheumatology

This page only lists publications with an associated author ORCID identifier.

Publications

Anna Eberhard, Daniela Di Giuseppe, Johan Askling, Stefan Bergman, Hannah Bower, Katerina Chatzidionysiou, Helena Forsblad-d'Elia, Alf Kastbom, Tor Olofsson, Thomas Frisell, Carl Turesson
Effectiveness of janus kinase inhibitors compared with biologic disease modifying anti-rheumatic drugs on pain reduction in rheumatoid arthritis: Results from a nationwide Swedish cohort study. Arthritis & rheumatology (Hoboken, N.J.) (2024)
M-L Karlsson, K Hertzberg-Nyquist, Saedis Saevarsdottir, Ingrid E Lundberg, Henrik Lindman, Susanne Pettersson, Katerina Chatzidionysiou
Evaluation of an individually tailored smoking-cessation intervention for patients with rheumatoid arthritis in an outpatient clinic. Scandinavian journal of rheumatology (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Hannah Bower, Thomas Frisell, Daniela di Giuseppe, Bénédicte Delcoigne, Ulf Lindström, Carl Turesson, Katerina Chatzidionysiou, Elisabet Lindqvist, Ann Knight, Helena Forsblad-d'Elia, Johan Askling
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden. RMD open 9 (4) (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Hannah Bower, Thomas Frisell, Daniela di Giuseppe, Bénédicte Delcoigne, Ulf Lindström, Carl Turesson, Katerina Chatzidionysiou, Elisabet Lindqvist, Ann Knight, Helena Forsblad-d'Elia, Johan Askling
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden. RMD open 9 (4) (2023)
Hannah Bower, Thomas Frisell, Daniela di Giuseppe, Bénédicte Delcoigne, Ulf Lindström, Carl Turesson, Katerina Chatzidionysiou, Elisabet Lindqvist, Ann Knight, Helena Forsblad-d'Elia, Johan Askling
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden. RMD open 9 (4) (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Katerina Chatzidionysiou, Daniela di Giuseppe, Jonas Soderling, Anca Catrina, Johan Askling
Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking. RMD open 8 (2) (2022)
Josef S Smolen, Robert B M Landewe, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher John Edwards, Kimmie L Hyrich, Janet E Pope, Savia de Souza, Tanja Alexandra Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin L Winthrop, Alejandro Balsa, Joan M Bathon, Maya H Buch, Gerd-Rüdiger R Burmester, Frank Buttgereit, Mario Humberto Cardiel, Katerina Chatzidionysiou, Catalin Codreanu, Maurizio Cutolo, Alfons A den Broeder, Khadija El Aoufy, Axel Finckh, João Eurico Fonseca, Jacques-Eric Gottenberg, Espen A Haavardsholm, AnnaMaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B McInnes, Eduardo F Mysler, Peter Nash, Gyula Poor, Gorica G Ristic, Felice Rivellese, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Nikolay Stoilov, Anja Strangfeld, Annette van der Helm-van Mil, Elsa van Duuren, Thea P M Vliet Vlieland, René Westhovens, Désirée Mfm van der Heijde
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the rheumatic diseases (2022)
Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, Bénédicte Delcoigne, Gerd-Marie Ahlenius, Eva Baecklund, Katerina Chatzidionysiou, Nils Feltelius, Helena Forsblad-d'Elia, Alf Kastbom, Lars Klareskog, Elisabet Lindqvist, Ulf Lindström, Carl Turesson, Christopher Sjöwall, Johan Askling, null null
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Annals of the rheumatic diseases (2021)
Vijay Joshua, Aase Haj Hensvold, Gudrun Reynisdottir, Monica Hansson, Martin Cornillet, Leonor Nogueira, Guy Serre, Sven Nyren, Reza Karimi, Anders Eklund, Magnus Sköld, Johan Grunewald, Katerina Chatzidionysiou, Anca Catrina
Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis. RMD open 6 (2) (2021)
Hannah Bower, Thomas Frisell, Daniela di Giuseppe, Bénédicte Delcoigne, Gerd-Marfie Ahlenius, Eva Baecklund, Katerina Chatzidionysiou, Nils Feltelius, Helena Forsblad-d'Elia, Alf Kastbom, Lars Klareskog, Elisabet Lindqvist, Ulf Lindström, Carl Turesson, Christopher Sjöwall, Johan Askling, null null
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD open 7 (3) (2021)
Katerina Chatzidionysiou, Bénédicte Delcoigne, Thomas Frisell, Merete L Hetland, Bente Glintborg, Lene Dreyer, René Cordtz, Kristian Zobbe, Dan Nordström, Nina Trokovic, Kalle Aaltonen, Sella Aarrestad Provan, Gerdur Grondal, Bjorn Gudbjornsson, Johan Askling
How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers. RMD open 6 (2) (2021)
Katerina Chatzidionysiou, Alexandra Circiumaru, Bence Rethi, Vijay Joshua, Marianne Engstrom, Aase Hensvold, Erik Af Klint, Anca Catrina
Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL. RMD open 7 (2) (2021)
Katerina Chatzidionysiou, Evangelia Samoli, Petros P Sfikakis, Maria G G Tektonidou
Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al' by Bettiol et al. Annals of the rheumatic diseases (2020)
Katerina Chatzidionysiou, Matina Liapi, Georgios Tsakonas, Iva Gunnarsson, Anca Catrina
Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift? Clinical rheumatology 40 (5) (2020)
Katerina Chatzidionysiou, Elisabet Svenungsson, Francesca Faustini
Could severe COVID-19 be considered a complementopathy? Lupus science & medicine 7 (1) (2020)
Katerina Chatzidionysiou, Evangelia Samoli, Petros P Sfikakis, Maria G G Tektonidou
Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus. Annals of the rheumatic diseases 79 (2) (2019)
Katerina Chatzidionysiou, Petros P Sfikakis
Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift. RMD open 5 (2) (2019)